1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemsowed Holding AB (PUBL) – PUBLISHES FULL YEAR REPORT 2022

MAR

Magle Chemoswed Holding AB (publ), an established innovation led healthcare group with proven growth through risk diversification and focus on high-value revenue streams, today publishes the interim report for the fourth quarter 2022 and the full year 2022.

SOLID REVENUES WITH INCREASED RETURNS

OCTOBER – DECEMBER 2022

  • Net sales amounted to 45.9 MSEK (35.9)
  • EBITDA equalled 5.9 MSEK (4.4)
  • Operating profit (EBIT) is 2.9 MSEK (1.3)
  • Profit after tax amounted to 0.8 MSEK (1.2)
  • Earnings per share SEK 0.1 (0.1) per share

JANUARY – DECEMBER 2022

  • Net sales amounted to 145.7 MSEK (132.1)
  • EBITDA equalled 25.5 MSEK (16.8).
  • Operating profit (EBIT) is 12.5 MSEK (5.2)
  • Profit after tax amounted to 9.4 MSEK (4.2)
  • Earnings per share SEK 0.9 (0.4) per share

Justin Pierce, CEO of Magle Chemoswed Holding AB, commented, “Looking back at the year 2022, we can conclude that Magle Group has made significant progress in the efforts of generating steadily growing revenues and profit based on its DSM (Degradable Starch Microsphere) material science platform and state-of-the-art CDMO business.”

EVENTS DURING THE REPORTING PERIOD

  • AXXO Woundgel launched in Kuwait
  • EmboCept® S registered in Argentina
  • SmartPAN® ViP study completed


EVENTS AFTER THE REPORTING PERIOD

  • Investment to expand CDMO fill and finish production capabilities has commenced in Q1, 2023

The full report can be downloaded at https://maglegroup.com/financial-reports/

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-16 08:00 CET.

Attachments

MagleGroup Q4 2022

Datum 2023-02-16, kl 08:00
Källa MFN
Bifogade filer
MagleGroup Q4 2022
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.